Skip to content

Ovarian Cancer Research Alliance

Gynecologic Cancer Advocates Converge on Capitol Hill for OCRA's Spring Advocacy Day

OCRA Advocate Leaders from nearly 40 states and Washington, DC, urged Congress to invest an additional $10 million in federal gynecologic cancer research and education programs, drawing attention beyond the Hill.

Only OCRA combines a laser focus with a panoramic view.

Funding Breakthrough Research

OCRA has invested $140 million toward finding a cure for ovarian and gynecologic cancers.

Discover our research

Supporting You Every Step of The Way

OCRA’s groundbreaking programs help 140,000 people each year navigate an overwhelming diagnosis, aiding patients and families when they need it most.

Find support

Advocacy is the Lifeblood of Change

OCRA advocates on Capitol Hill to improve research and education, drug and diagnostic safety, and access to quality care for all members of the ovarian and gynecologic cancer community. To date, OCRA has helped secure more than $3.8 billion in federal funding.

Take action now
A woman wearing sunglasses and a gray shirt kisses a small child on the lips. The child, dressed in a yellow shirt with a Disney character and a yellow bow in her hair, looks content. They are outdoors with trees and greenery in the background.

Genetic testing can save your life.

Knowledge is power. Genetic testing can lower your risk of ovarian and gynecologic cancers.

The power of shared experiences

Join our Staying Connected Support Series, Woman to Woman Peer Mentor Program, or online community for knowledge, connection, support, and hope.

A Message from President and CEO Audra Moran

Get Involved

Join us as we drive innovation, offer hope, and invest in groundbreaking research that saves lives.

There are so many ways to lend a hand and improve the lives of thousands of ovarian and gynecologic cancer patients and their families.

News & Updates

FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer

FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer

On March 25, 2026, the FDA approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab).  The approval follows last month’s FDA approval of Keytruda (pembrolizumab) with … Continued

Read more

The Overview: March 2026

The Overview: March 2026

OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued

Read more

April Programs: New Offerings, Fresh Topics, and More

April Programs: New Offerings, Fresh Topics, and More

April is a full month at OCRA, with several new programs joining our ongoing lineup of workshops, educational sessions, and community events. Whether you’re looking for practical guidance, clinical information, or simply a chance to connect and create, there’s something here for you. New and Expanded Programs Advanced Care Planning Workshop Series April 6, 13, … Continued

Read more

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.